Manuel Perez Alonso

Manuel Perez Alonso

  • Professor of Genetics
  • University of Valencia
  • Spain
Biography:

Manuel Pérez Alonso is a Professor of the Department of Genetics at the University of Valencia and there he founded the Laboratory of Molecular Genetics of Development. He is the co-director of the master’s in medical Genetics and Genomics at the University of Valencia, pain. In his laboratory, he has developed more than twenty research projects funded by various national and international organizations. He completed his Ph.D. in Molecular Genetics from the University of Lund, Sweden.

He is a pioneer in the field of scientific entrepreneurship In Spain. Dr. Pérez Alonso leads (Founder & Scientific Advisor) the Institute of Genomic Medicine (Imegen), with specialization in genetic analysis. He is also the author of three patents licensed by the biotechnology industry. He is the author of more than 50 research papers on his field of expertise, including three articles published by the prestigious journal Nature. As a scientific entrepreneur, he is a founding partner of the company Sistemas Genómicos (Genomic Systems), Valentia BioPharma and the Genomic Medicine Institute, among others.

He has been Roche's scientific advisor in the field of DNA sequencing. For twelve years, from its foundation in 1998 to April 2009, it has been the promoter and founding partner of the company Sistemas Genómicos SL, where he held the position of Scientific and Strategic Director. He was a founding partner and Scientific Director of the company Valentia BioPharma and the Institute of Genomic Medicine, both located in the Scientific Park of the University of Valencia. Among other projects, his collaboration with the multinational Life Technologies, in the development of applications of the ultrasecuenciación of genomes through the technology SOLiD stands out.

Research Interest
Molecular Genetics and Genomics applied to Medicine, Genomic tools for genetic diagnosis in cancer and rare diseases, biopharmaceutical research to combat rare genetic diseases

Join Our Newsletter